These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

601 related articles for article (PubMed ID: 31736230)

  • 1. TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors.
    Gymnopoulos M; Betancourt O; Blot V; Fujita R; Galvan D; Lieuw V; Nguyen S; Snedden J; Stewart C; Villicana J; Wojciak J; Wong E; Pardo R; Patel N; D'Hooge F; Vijayakrishnan B; Barry C; Hartley JA; Howard PW; Newman R; Coronella J
    Mol Oncol; 2020 Jan; 14(1):54-68. PubMed ID: 31736230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A MET Targeting Antibody-Drug Conjugate Overcomes Gemcitabine Resistance in Pancreatic Cancer.
    Cazes A; Betancourt O; Esparza E; Mose ES; Jaquish D; Wong E; Wascher AA; Tiriac H; Gymnopoulos M; Lowy AM
    Clin Cancer Res; 2021 Apr; 27(7):2100-2110. PubMed ID: 33451980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4.
    Harper J; Lloyd C; Dimasi N; Toader D; Marwood R; Lewis L; Bannister D; Jovanovic J; Fleming R; D'Hooge F; Mao S; Marrero AM; Korade M; Strout P; Xu L; Chen C; Wetzel L; Breen S; van Vlerken-Ysla L; Jalla S; Rebelatto M; Zhong H; Hurt EM; Hinrichs MJ; Huang K; Howard PW; Tice DA; Hollingsworth RE; Herbst R; Kamal A
    Mol Cancer Ther; 2017 Aug; 16(8):1576-1587. PubMed ID: 28522587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers.
    Fujita R; Blot V; Wong E; Stewart C; Lieuw V; Richardson R; Banah A; Villicana J; Timmer A; Coronella J; Newman R; Gymnopoulos M
    Cancer Biol Ther; 2020 Jun; 21(6):549-559. PubMed ID: 32192391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
    Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
    BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral Payload Concentration Correlates with the Activity of Antibody-Drug Conjugates.
    Zhang D; Yu SF; Khojasteh SC; Ma Y; Pillow TH; Sadowsky JD; Su D; Kozak KR; Xu K; Polson AG; Dragovich PS; Hop CECA
    Mol Cancer Ther; 2018 Mar; 17(3):677-685. PubMed ID: 29348271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers.
    Zammarchi F; Havenith KE; Chivers S; Hogg P; Bertelli F; Tyrer P; Janghra N; Reinert HW; Hartley JA; van Berkel PH
    Mol Cancer Ther; 2022 Apr; 21(4):582-593. PubMed ID: 35086955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody-Drug Conjugates Containing a Low-Potency Pyrrolobenzodiazepine Dimer.
    Gregson SJ; Pugh K; Patel N; Afif-Rider S; Vijayakrishnan B; Santos K; Riedl J; Hutchinson I; Kang GD; Chooi KP; Beard R; Adams L; Barry CS; Ball K; Masterson LA; McFarlane M; Hartley JA; Howard PW
    Mol Cancer Ther; 2022 Sep; 21(9):1439-1448. PubMed ID: 35793464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SHR-A1403, a novel c-Met antibody-drug conjugate, exerts encouraging anti-tumor activity in c-Met-overexpressing models.
    Yang CY; Wang L; Sun X; Tang M; Quan HT; Zhang LS; Lou LG; Gou SH
    Acta Pharmacol Sin; 2019 Jul; 40(7):971-979. PubMed ID: 30643210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-Lock linker.
    Shi B; Wu M; Li Z; Xie Z; Wei X; Fan J; Xu Y; Ding D; Akash SH; Chen S; Cao S
    Cancer Med; 2019 Apr; 8(4):1793-1805. PubMed ID: 30843650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel polyamide-pyrrolobenzodiazepine hybrids for antibody-drug conjugates.
    Thomas JD; Yurkovetskiy AV; Yin M; Bodyak ND; Gumerov DR; Tang S; Kelleher E; Jones BD; Protopopova M; Qin L; Uttard A; Demady DR; Lowinger TB
    Bioorg Med Chem Lett; 2022 Sep; 72():128876. PubMed ID: 35788036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies.
    Rios-Doria J; Harper J; Rothstein R; Wetzel L; Chesebrough J; Marrero A; Chen C; Strout P; Mulgrew K; McGlinchey K; Fleming R; Bezabeh B; Meekin J; Stewart D; Kennedy M; Martin P; Buchanan A; Dimasi N; Michelotti E; Hollingsworth R
    Cancer Res; 2017 May; 77(10):2686-2698. PubMed ID: 28283653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies.
    Flynn MJ; Zammarchi F; Tyrer PC; Akarca AU; Janghra N; Britten CE; Havenith CE; Levy JN; Tiberghien A; Masterson LA; Barry C; D'Hooge F; Marafioti T; Parren PW; Williams DG; Howard PW; van Berkel PH; Hartley JA
    Mol Cancer Ther; 2016 Nov; 15(11):2709-2721. PubMed ID: 27535974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimer.
    White JB; Fleming R; Masterson L; Ruddle BT; Zhong H; Fazenbaker C; Strout P; Rosenthal K; Reed M; Muniz-Medina V; Howard P; Dixit R; Wu H; Hinrichs MJ; Gao C; Dimasi N
    MAbs; 2019 Apr; 11(3):500-515. PubMed ID: 30835621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel cMET-targeting antibody Fab drug conjugates as potential treatment for solid tumors with highly expressed cMET.
    Lim RK; Buschman M; Khasanov A; Ledesma A; Chen J; Nguyen T; Guo J; Li L; Huang J; Niu J; Kerwin L; Wang R; Guo Y; Zhu T; Kaufmann G; Zhang Y; Zhou H; Ji H; Fu Y
    Expert Opin Biol Ther; 2023; 23(11):1137-1149. PubMed ID: 38078403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Luteolin exerts a marked antitumor effect in cMet-overexpressing patient-derived tumor xenograft models of gastric cancer.
    Lu J; Li G; He K; Jiang W; Xu C; Li Z; Wang H; Wang W; Wang H; Teng X; Teng L
    J Transl Med; 2015 Feb; 13():42. PubMed ID: 25638174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models.
    Gavine PR; Ren Y; Han L; Lv J; Fan S; Zhang W; Xu W; Liu YJ; Zhang T; Fu H; Yu Y; Wang H; Xu S; Zhou F; Su X; Yin X; Xie L; Wang L; Qing W; Jiao L; Su W; Wang QM
    Mol Oncol; 2015 Jan; 9(1):323-33. PubMed ID: 25248999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody-Drug Conjugates with Self-Immolative Disulfide Linkers.
    Pillow TH; Schutten M; Yu SF; Ohri R; Sadowsky J; Poon KA; Solis W; Zhong F; Del Rosario G; Go MAT; Lau J; Yee S; He J; Liu L; Ng C; Xu K; Leipold DD; Kamath AV; Zhang D; Masterson L; Gregson SJ; Howard PW; Fang F; Chen J; Gunzner-Toste J; Kozak KK; Spencer S; Polakis P; Polson AG; Flygare JA; Junutula JR
    Mol Cancer Ther; 2017 May; 16(5):871-878. PubMed ID: 28223423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110.
    Domínguez JM; Pérez-Chacón G; Guillén MJ; Muñoz-Alonso MJ; Somovilla-Crespo B; Cibrián D; Acosta-Iborra B; Adrados M; Muñoz-Calleja C; Cuevas C; Sánchez-Madrid F; Avilés P; Zapata JM
    J Hematol Oncol; 2020 Apr; 13(1):32. PubMed ID: 32264921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen.
    Wang X; Ma D; Olson WC; Heston WD
    Mol Cancer Ther; 2011 Sep; 10(9):1728-39. PubMed ID: 21750220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.